[go: up one dir, main page]

MA31434B1 - Nouveaux sels de piperazine en tant qu'antagonistes de d2/d3 - Google Patents

Nouveaux sels de piperazine en tant qu'antagonistes de d2/d3

Info

Publication number
MA31434B1
MA31434B1 MA32405A MA32405A MA31434B1 MA 31434 B1 MA31434 B1 MA 31434B1 MA 32405 A MA32405 A MA 32405A MA 32405 A MA32405 A MA 32405A MA 31434 B1 MA31434 B1 MA 31434B1
Authority
MA
Morocco
Prior art keywords
antagonists
salts
solvates
hydrates
compounds
Prior art date
Application number
MA32405A
Other languages
Arabic (ar)
English (en)
Inventor
Csongor Éva Ágainé
László Czibula
Ferenc Sebök
György Domány
István Greiner
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MA31434B1 publication Critical patent/MA31434B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

L'invention concerne de nouveaux sels de monohydrochlorure, de dihydrochlorure, de monohydrobromure, de maléate et de méthanesulfonate de trans 4-{2-[4-(2,3- dichlorophényl)-pipérazine-1-yl]-éthyl}-n,n-diméthylcarbamoyl-cyclohexylamine et/ou leurs hydrates et/ou solvates. L'invention concerne de plus un procédé de préparation de ces sels et de leurs hydrates et/ou solvates, l'utilisation de ces composés pour traiter et/ou prévenir des états pathologiques nécessitant une modulation des récepteurs dopaminergiques ainsi que des compositions pharmaceutiques contenant ces composés.
MA32405A 2007-05-11 2009-12-07 Nouveaux sels de piperazine en tant qu'antagonistes de d2/d3 MA31434B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700339A HU230748B1 (hu) 2007-05-11 2007-05-11 Új piperazin só és előállítási eljárása
PCT/HU2008/000044 WO2008139235A2 (fr) 2007-05-11 2008-05-13 Nouveaux sels de pipérazine comme antagonistes des récepteurs dopaminergiques d3/d2

Publications (1)

Publication Number Publication Date
MA31434B1 true MA31434B1 (fr) 2010-06-01

Family

ID=89987512

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32405A MA31434B1 (fr) 2007-05-11 2009-12-07 Nouveaux sels de piperazine en tant qu'antagonistes de d2/d3

Country Status (34)

Country Link
US (1) US7943621B2 (fr)
EP (1) EP2155696B1 (fr)
JP (1) JP2010526861A (fr)
KR (2) KR101668973B1 (fr)
CN (1) CN101679315B (fr)
AP (1) AP2009005012A0 (fr)
AU (1) AU2008249772B2 (fr)
BR (1) BRPI0811199A2 (fr)
CA (1) CA2684404C (fr)
CO (1) CO6241112A2 (fr)
CY (1) CY1119076T1 (fr)
DK (1) DK2155696T3 (fr)
EA (1) EA017270B1 (fr)
EC (1) ECSP099772A (fr)
ES (1) ES2628025T3 (fr)
GE (1) GEP20125522B (fr)
HR (1) HRP20170918T1 (fr)
HU (2) HU230748B1 (fr)
IL (1) IL201533A0 (fr)
LT (1) LT2155696T (fr)
MA (1) MA31434B1 (fr)
MX (1) MX2009012182A (fr)
MY (1) MY148078A (fr)
NI (1) NI200900203A (fr)
NZ (1) NZ580642A (fr)
PL (1) PL2155696T3 (fr)
PT (1) PT2155696T (fr)
RS (1) RS56036B1 (fr)
SI (1) SI2155696T1 (fr)
TN (1) TN2009000458A1 (fr)
TW (1) TWI424846B (fr)
UA (1) UA102225C2 (fr)
WO (1) WO2008139235A2 (fr)
ZA (1) ZA200907511B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100027137A (ko) * 2007-05-11 2010-03-10 리히터 게데온 닐트. 카르바모일-사이클로헥산 유도체의 신규한 용매화물 및 결정 형태
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HRP20171908T1 (hr) * 2007-08-03 2018-01-26 Richter Gedeon Nyrt. Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CN102014909B (zh) * 2008-02-21 2013-03-13 田边三菱制药株式会社 口服用固体制剂
RS53866B1 (sr) 2008-07-16 2015-08-31 Richter Gedeon Nyrt. Farmaceutske formulacije koje sadrže ligande dopaminskih receptora
HU230067B1 (hu) * 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105B (zh) * 2015-09-22 2019-10-11 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018229794A1 (fr) 2017-06-13 2018-12-20 Cipla Limited Forme amorphe de cariprazine
WO2019016828A1 (fr) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center Nouveaux procédés pour la préparation de chlorhydrate de trans-n-{4-[2-[4-(2,3-dichlorophényl)pipérazine-1-yl]éthyl] cyclohexyl}-n',n'-diméthyl urée et polymorphes de celui-ci
WO2020056929A1 (fr) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 Nouvelle forme cristalline de chlorhydrate de cariprazine, procédé de préparation et utilisation de la nouvelle forme cristalline de chlorhydrate de cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
JP7537811B2 (ja) * 2020-08-26 2024-08-21 上海雲晟研新生物科技有限公司 カリプラジン医薬組成物、製造方法及び応用
WO2023077094A1 (fr) * 2021-10-28 2023-05-04 Abbvie Inc. Traitement d'un trouble dépressif majeur
JP2025508811A (ja) * 2022-02-22 2025-04-10 上海雲晟研新生物科技有限公司 カリプラジン薬用塩及びその結晶形、医薬組成物、製造方法並びに使用
WO2024072930A1 (fr) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agonistes partiels du récepteur d3/d2 de la dopamine destinés au traitement de troubles neuropsychiatriques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
TWI424846B (zh) 2014-02-01
JP2010526861A (ja) 2010-08-05
NZ580642A (en) 2012-02-24
HUP0700339A3 (en) 2010-01-28
US7943621B2 (en) 2011-05-17
DK2155696T3 (en) 2017-07-10
HUE034796T2 (en) 2018-03-28
EP2155696A2 (fr) 2010-02-24
AU2008249772A1 (en) 2008-11-20
MY148078A (en) 2013-02-28
NI200900203A (es) 2010-03-11
EA017270B1 (ru) 2012-11-30
MX2009012182A (es) 2009-12-09
ECSP099772A (es) 2009-12-28
AU2008249772B2 (en) 2013-09-05
CO6241112A2 (es) 2011-01-20
LT2155696T (lt) 2017-06-12
PT2155696T (pt) 2017-06-02
KR20100018493A (ko) 2010-02-17
EA200971046A1 (ru) 2010-04-30
CA2684404A1 (fr) 2008-11-20
HU230748B1 (hu) 2018-02-28
HU0700339D0 (en) 2007-07-30
WO2008139235A3 (fr) 2009-03-12
HRP20170918T1 (hr) 2017-09-22
WO2008139235A2 (fr) 2008-11-20
KR101668973B1 (ko) 2016-10-24
HK1140473A1 (en) 2010-10-15
EP2155696B1 (fr) 2017-03-22
CY1119076T1 (el) 2018-01-10
CA2684404C (fr) 2013-02-05
ES2628025T3 (es) 2017-08-01
PL2155696T3 (pl) 2017-10-31
HUP0700339A2 (en) 2009-04-28
KR20150090264A (ko) 2015-08-05
RS56036B1 (sr) 2017-09-29
BRPI0811199A2 (pt) 2014-10-29
SI2155696T1 (sl) 2017-08-31
TW201002323A (en) 2010-01-16
CN101679315B (zh) 2013-06-12
AP2009005012A0 (en) 2009-10-31
US20090023750A1 (en) 2009-01-22
GEP20125522B (en) 2012-05-25
TN2009000458A1 (en) 2011-03-31
WO2008139235A8 (fr) 2009-12-03
IL201533A0 (en) 2010-05-31
ZA200907511B (en) 2010-07-28
UA102225C2 (ru) 2013-06-25
CN101679315A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
MA31434B1 (fr) Nouveaux sels de piperazine en tant qu'antagonistes de d2/d3
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
TN2011000316A1 (fr) Derives de sulfonamides
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
ME00901B (me) Mezilat trihidrat 5-(2-(4-(1 ,2-benzizotiazol-3-il)-1-piperazinil)-etil)-6-hlor0-1,3-dihidr0-2h-indol-2-ona
NO20072435L (no) CGRP-reseptorantagonister
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
MX2009008773A (es) Derivados de 3,4-dihidro-1,4-benzoxazina,3,4-dihidro-1,4-benzotiaz ina y 1,2,3,4-tetrahidro-quinoxalina como agonistas de adrenoreceptores alfa2c.
MA35184B1 (fr) Antagonistes de trpv4
MA30420B1 (fr) Derives de terphenyle pour le traitment de la maladie d'alzheimer
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
NZ585085A (en) Method of treating arthritis using arylsulfonamide compounds
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
MA59895B1 (fr) Composés spiro en tant qu'antagonistes du récepteur de la mélanocortine 4 et leurs utilisations
MA49127B1 (fr) Dérivés d'indole n-substitués
EP4162937A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la maladie de parkinson, comprenant un composé du type 2-(4-(1-hydroxypropane-2-yl)phényl)isoindolin-1-one
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
MY148406A (en) 4-[(3-fluorophenoxy)phenylmethyl] piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
RU2443697C1 (ru) Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
MX2007001992A (es) Antagonistas del receptor 5-ht7.